Curcumin and resveratrol suppress dextran sulfate sodiuminduced colitis in mice.
Mol Med Rep
; 19(4): 3053-3060, 2019 Apr.
Article
em En
| MEDLINE
| ID: mdl-30816479
ABSTRACT
Curcumin and resveratrol are two natural products, which have been described as potential antiinflammatory, antitumor, and antioxidant molecules. The aims of the present study were to investigate the protective effect of curcumin and resveratrol on dextran sulfate sodium (DSS)induced ulcerative colitis (UC) in mice, in addition to understanding the underlying molecular mechanisms. In order to accomplish this, BALB/c mice received drinking water containing 3.5% DSS. Curcumin (50 mg/kg/day) or resveratrol (80 mg/kg/day) were administered orally for 7 days. Survival rate, body weight, disease activity index score, colon length, proinflammatory cytokines, and the expression autophagyassociated proteins, and mechanistic target of rapamycin (mTOR) and sirtuin 1 (SIRT1) were measured. Curcumin or resveratrol treatment prolonged the survival of mice with UC, reduced body weight loss and attenuated the severity of the disease compared with the DSStreated mice. This effect was associated with a substantial clinical amelioration of the disruption of the colonic architecture and a significant reduction in proinflammatory cytokine production. Furthermore, curcumin or resveratrol significantly downregulated the expression of autophagyrelated 12, Beclin1 and microtubuleassociated protein light chain 3 II, and upregulated the expression of phosphorylated mTOR and SIRT1 in the colon tissue, compared with those in the DSStreated group. These results suggest that curcumin and resveratrol exert protective effects on DSSinduced UC, partially through suppressing the intestinal inflammatory cascade reaction, reducing autophagy and regulating SIRT1/mTOR signaling.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Colite
/
Curcumina
/
Resveratrol
/
Anti-Inflamatórios
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Mol Med Rep
Ano de publicação:
2019
Tipo de documento:
Article